Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

Alkermes plc (NASDAQ: ALKS) today announced that data from studies of the company's pipeline of central nervous system (CNS) drug candidates in schizophrenia and depression, including ALKS 3831, aripiprazole lauroxil and ALKS 5461, will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Fla., June 22-25, 2015. Alkermes data presentations at ASCP include: ALKS 3831 Oral presentation, "ALKS 3831: A Novel Drug Candidate for the Treatment of Schizophrenia," will be presented during the Pharmaceutical Pipeline symposium on Monday, June 22, 2015, 2:00 p.m. – 4:00 p.m. EDT. Poster #T6, "ALKS 3831: A Novel Drug Candidate for the Treatment of Schizophrenia," will be available during Poster Session I, Tuesday, June 23, 2015, 11:15 a.m. – 1:00 p.m. EDT. Oral presentation, "A Phase 2, Randomized, Olanzapine-Controlled Study of the Safety, Tolerability and Efficacy of ALKS 3831 in Adults with Schizophrenia," will be presented on Tuesday, June 23, 2015, 3:30 p.m. – 4:30 p.m. EDT. Aripiprazole Lauroxil Poster #T88, "Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles, and Related Safety Considerations in Acute Schizophrenia," will be available during Poster Session I, Tuesday, June 23, 2015, 11:15 a.m. – 1:00 p.m. EDT. Oral presentation, "Efficacy and Safety of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia: Results from a Double-Blind Placebo-Controlled Study," will be presented on Tuesday, June 23, 2015, 3:30 p.m. – 4:30 p.m. EDT. Poster #W88, "Effect of Aripiprazole Lauroxil on Personal and Social Functioning and Health-Related Quality of Life Among Patients with Schizophrenia," will be available during Poster Session II, Wednesday, June 24, 2015, 12:00 p.m. – 2:00 p.m. EDT. ALKS 5461 Oral presentation "ALKS 5461 as Adjunctive Treatment of Major Depressive Disorder: Phase 3, Randomized, Double-Blind Study (FORWARD-1) Evaluating Two Titration Schedules," will be presented on Tuesday, June 23, 2015, 3:30 p.m. – 4:30 p.m. EDT. Poster #W36, "Combinations of Buprenorphine and Samidorphan Modulate Glutamate and GABA Transmission in the Medial Prefrontal Cortex and Ventral Hippocampus of Male Wistar Rats," will be available during Poster Session II, Wednesday, June 24, 2015, 12:00 p.m. – 2:00 p.m. EDT. A full list of all presentations at the ASCP meeting is available at: http://ascpmeeting.org/. Conference CallAlkermes will host a conference call on Tuesday, June 23, 2015, at 8:00 a.m. EDT (1:00 p.m. BST), to discuss the six-month data of ALKS 3831 for the treatment of schizophrenia. The data will be reviewed by management, followed by a discussion with Dr. Peter Weiden, Professor of Psychiatry at the University of Illinois Medical Center, on the treatment landscape for schizophrenia. The conference call may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988. The conference call will also be webcast on the Investors section of Alkermes' website at www.alkermes.com. In addition, a replay of the conference call will be available from 10:30 a.m. EDT (3:30 p.m. BST) on Tuesday, June 23, 2015, through 5:00 p.m. EDT (10:00 p.m. BST) on Tuesday, June 30, 2015, and may be accessed by visiting Alkermes' website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.